<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">
<pdf2xml producer="poppler" version="23.04.0">
<page number="1" position="absolute" top="0" left="0" height="792" width="612">
	<fontspec id="font0" size="9" family="Arial,Italic" color="#000000"/>
	<fontspec id="font1" size="9" family="Arial" color="#000000"/>
	<fontspec id="font2" size="9" family="Arial,Bold" color="#000000"/>
	<fontspec id="font3" size="7" family="Arial,Italic" color="#000000"/>
	<fontspec id="font4" size="11" family="GillSans,Bold" color="#000000"/>
	<fontspec id="font5" size="10" family="Giovanni-Book" color="#000000"/>
<text top="41" left="55" width="254" height="10" font="font0" id="p1_t1" reading_order_no="0" segment_no="0" tag_type="title">Current Controlled Trials in Cardiovascular Medicine 2005, 6 :15<i>Current Controlled Trials in Cardiovascular Medicine</i></text>
<text top="41" left="373" width="181" height="10" font="font1" id="p1_t2" reading_order_no="1" segment_no="1" tag_type="text">http://cvm.controlled-trials.com/content/6/1/15</text>
<text top="756" left="508" width="46" height="10" font="font1" id="p1_t3" reading_order_no="107" segment_no="10" tag_type="text">Page 2 of 9<b>6</b></text>
<text top="769" left="432" width="122" height="8" font="font3" id="p1_t4" reading_order_no="108" segment_no="11" tag_type="text">(page number not for citation purposes)</text>
<text top="87" left="55" width="60" height="10" font="font4" id="p1_t5" reading_order_no="2" segment_no="2" tag_type="title">Background</text>
<text top="98" left="55" width="241" height="9" font="font5" id="p1_t6" reading_order_no="3" segment_no="4" tag_type="text">Coronary artery bypass graft surgery (CABG) is the most</text>
<text top="110" left="55" width="241" height="9" font="font5" id="p1_t7" reading_order_no="4" segment_no="4" tag_type="text">durable approach for the treatment of ischemic heart dis-<i>(page number not for citation purposes)</i></text>
<text top="122" left="55" width="241" height="9" font="font5" id="p1_t8" reading_order_no="5" segment_no="4" tag_type="text">ease [1], with &gt;400,000 procedures performed annually<b>Background</b></text>
<text top="134" left="55" width="241" height="9" font="font5" id="p1_t9" reading_order_no="6" segment_no="4" tag_type="text">in the United States alone [2]. Despite the increasing</text>
<text top="145" left="55" width="241" height="9" font="font5" id="p1_t10" reading_order_no="7" segment_no="4" tag_type="text">application of arterial conduits during CABG, the saphen-</text>
<text top="157" left="55" width="241" height="9" font="font5" id="p1_t11" reading_order_no="8" segment_no="4" tag_type="text">ous vein remains the most common conduit, employed<a href="">1</a>], with &gt;400,000 procedures performed annually</text>
<text top="169" left="55" width="241" height="9" font="font5" id="p1_t12" reading_order_no="9" segment_no="4" tag_type="text">for more than 70% of grafts [3]. However, saphenous vein<a href="">ates alone [2</a>]. Despite the increasing</text>
<text top="181" left="55" width="241" height="9" font="font5" id="p1_t13" reading_order_no="10" segment_no="4" tag_type="text">graft (SVG) disease presents an important clinical prob-</text>
<text top="192" left="55" width="241" height="9" font="font5" id="p1_t14" reading_order_no="11" segment_no="4" tag_type="text">lem. Even with aggressive medical therapy [4-11], up to</text>
<text top="204" left="55" width="241" height="9" font="font5" id="p1_t15" reading_order_no="12" segment_no="4" tag_type="text">15% of vein grafts occlude in the first year after bypass sur-<a href="">an 70% of grafts [3]. However</a>, saphenous vein</text>
<text top="216" left="55" width="241" height="9" font="font5" id="p1_t16" reading_order_no="13" segment_no="4" tag_type="text">gery. Between 1 and 6 years, the graft attrition rate is 1%</text>
<text top="228" left="55" width="241" height="9" font="font5" id="p1_t17" reading_order_no="14" segment_no="4" tag_type="text">to 2% per year, and between 6 and 10 years it rises to 4%<a href="">y [4-11</a>], up to</text>
<text top="239" left="55" width="241" height="9" font="font5" id="p1_t18" reading_order_no="15" segment_no="4" tag_type="text">per year. By 10 years after surgery, only 60% of grafts are</text>
<text top="251" left="55" width="241" height="9" font="font5" id="p1_t19" reading_order_no="16" segment_no="4" tag_type="text">patent and only 50% of patent vein grafts are free of sig-</text>
<text top="263" left="55" width="241" height="9" font="font5" id="p1_t20" reading_order_no="17" segment_no="4" tag_type="text">nificant stenosis. In addition, native coronary artery dis-</text>
<text top="275" left="55" width="241" height="9" font="font5" id="p1_t21" reading_order_no="18" segment_no="4" tag_type="text">ease progresses in 5% of patients annually [12-15].</text>
<text top="286" left="55" width="241" height="9" font="font5" id="p1_t22" reading_order_no="19" segment_no="4" tag_type="text">Reflecting the graft and native vessel attrition, this popu-</text>
<text top="298" left="55" width="241" height="9" font="font5" id="p1_t23" reading_order_no="20" segment_no="4" tag_type="text">lation is at high risk for subsequent ischemic events,</text>
<text top="310" left="55" width="241" height="9" font="font5" id="p1_t24" reading_order_no="21" segment_no="4" tag_type="text">including death, myocardial infarction (MI) and stroke<a href="">ally [12-15].</a></text>
<text top="322" left="55" width="241" height="9" font="font5" id="p1_t25" reading_order_no="22" segment_no="4" tag_type="text">[14]. Further revascularization, either reoperation or per-</text>
<text top="333" left="55" width="241" height="9" font="font5" id="p1_t26" reading_order_no="23" segment_no="4" tag_type="text">cutaneous coronary intervention, is required in 4% of</text>
<text top="345" left="55" width="241" height="9" font="font5" id="p1_t27" reading_order_no="24" segment_no="4" tag_type="text">patients by 5 years, 19% of patients by 10 years and 31%</text>
<text top="357" left="55" width="241" height="9" font="font5" id="p1_t28" reading_order_no="25" segment_no="4" tag_type="text">of patients by 12 years after the initial bypass surgery<a href="">[14]. Furth</a>er revascularization, either reoperation or per-</text>
<text top="369" left="55" width="28" height="9" font="font5" id="p1_t29" reading_order_no="26" segment_no="4" tag_type="text">[3,16].</text>
<text top="392" left="55" width="241" height="9" font="font5" id="p1_t30" reading_order_no="27" segment_no="6" tag_type="text">The process of SVG disease is composed of three mecha-</text>
<text top="404" left="55" width="241" height="9" font="font5" id="p1_t31" reading_order_no="28" segment_no="6" tag_type="text">nistically interlinked stages: thrombosis, intimal hyper-</text>
<text top="416" left="55" width="241" height="9" font="font5" id="p1_t32" reading_order_no="29" segment_no="6" tag_type="text">plasia, and atherosclerosis [13,14,16-18]. Early graft<a href="">[3,16</a>].</text>
<text top="427" left="55" width="241" height="9" font="font5" id="p1_t33" reading_order_no="30" segment_no="6" tag_type="text">thrombosis can occur at the time of surgery secondary to</text>
<text top="439" left="55" width="241" height="9" font="font5" id="p1_t34" reading_order_no="31" segment_no="6" tag_type="text">focal endothelial disruption [19,20]. Grafts that survive</text>
<text top="451" left="55" width="241" height="9" font="font5" id="p1_t35" reading_order_no="32" segment_no="6" tag_type="text">this early period develop a progressive thickening of the<a href="">is [13</a>,<a href="">14,16-18</a>]. Early graft</text>
<text top="463" left="55" width="241" height="9" font="font5" id="p1_t36" reading_order_no="33" segment_no="6" tag_type="text">media that begins within days after implantation. This</text>
<text top="474" left="55" width="241" height="9" font="font5" id="p1_t37" reading_order_no="34" segment_no="6" tag_type="text">process, termed intimal hyperplasia, is a consequence of<a href="">19,20</a>]. Grafts that survive</text>
<text top="486" left="55" width="241" height="9" font="font5" id="p1_t38" reading_order_no="35" segment_no="6" tag_type="text">smooth muscle cell proliferation and extracellular matrix</text>
<text top="498" left="55" width="241" height="9" font="font5" id="p1_t39" reading_order_no="36" segment_no="6" tag_type="text">protein synthesis [21,22]. Platelets play a fundamental</text>
<text top="510" left="55" width="241" height="9" font="font5" id="p1_t40" reading_order_no="37" segment_no="6" tag_type="text">role in the process of smooth muscle cell proliferation and</text>
<text top="521" left="55" width="241" height="9" font="font5" id="p1_t41" reading_order_no="38" segment_no="6" tag_type="text">intimal hyperplasia [23,24]. Intimal hyperplasia is</text>
<text top="533" left="55" width="241" height="9" font="font5" id="p1_t42" reading_order_no="39" segment_no="6" tag_type="text">present in all grafts 1 month after implantation [25] and<a href="">[21,22]. Platelets play </a>a fundamental</text>
<text top="545" left="55" width="241" height="9" font="font5" id="p1_t43" reading_order_no="40" segment_no="6" tag_type="text">forms a template for the development of superimposed</text>
<text top="557" left="55" width="241" height="9" font="font5" id="p1_t44" reading_order_no="41" segment_no="6" tag_type="text">atherosclerotic changes [17,18]. With the passage of a suf-<a href="">23,24]. Intim</a>al hyperplasia is</text>
<text top="568" left="55" width="241" height="9" font="font5" id="p1_t45" reading_order_no="42" segment_no="6" tag_type="text">ficient period of time, the thrombotic occlusion of vein<a href="">25]</a> and</text>
<text top="580" left="55" width="241" height="9" font="font5" id="p1_t46" reading_order_no="43" segment_no="6" tag_type="text">grafts is almost inevitable due to progressive atherosclero-</text>
<text top="592" left="55" width="33" height="9" font="font5" id="p1_t47" reading_order_no="44" segment_no="6" tag_type="text">sis [17].<a href="">17,18]. Wit</a>h the passage of a suf-</text>
<text top="615" left="55" width="241" height="9" font="font5" id="p1_t48" reading_order_no="45" segment_no="8" tag_type="text">Despite its established benefit in patients with coronary</text>
<text top="627" left="55" width="241" height="9" font="font5" id="p1_t49" reading_order_no="46" segment_no="8" tag_type="text">artery disease, aspirin therapy has numerous limitations.</text>
<text top="639" left="55" width="241" height="9" font="font5" id="p1_t50" reading_order_no="47" segment_no="8" tag_type="text">It is a relatively weak antiplatelet agent and has no effect<a href="">17]</a>.</text>
<text top="651" left="55" width="241" height="9" font="font5" id="p1_t51" reading_order_no="48" segment_no="8" tag_type="text">on thrombin, which is believed to play a major role in</text>
<text top="662" left="55" width="241" height="9" font="font5" id="p1_t52" reading_order_no="49" segment_no="8" tag_type="text">acute coronary syndrome [26]. Even with aspirin therapy</text>
<text top="674" left="55" width="241" height="9" font="font5" id="p1_t53" reading_order_no="50" segment_no="8" tag_type="text">for secondary prevention, a large number of recurrent</text>
<text top="686" left="55" width="241" height="9" font="font5" id="p1_t54" reading_order_no="51" segment_no="8" tag_type="text">events occur [27]. A significant proportion of patients</text>
<text top="698" left="55" width="241" height="9" font="font5" id="p1_t55" reading_order_no="52" segment_no="8" tag_type="text">undergoing CABG may be aspirin resistant, defined as<a href="">rome [26]. Ev</a>en with aspirin therapy</text>
<text top="709" left="55" width="241" height="9" font="font5" id="p1_t56" reading_order_no="53" segment_no="8" tag_type="text">undetectable platelet inhibition after one week of therapy</text>
<text top="721" left="55" width="241" height="9" font="font5" id="p1_t57" reading_order_no="54" segment_no="8" tag_type="text">[28,29]. Depending on the population studied and the<a href="">cur [27]. A si</a>gnificant proportion of patients</text>
<text top="87" left="313" width="241" height="9" font="font5" id="p1_t58" reading_order_no="55" segment_no="3" tag_type="text">specific definition of aspirin resistance, anywhere from</text>
<text top="98" left="313" width="241" height="9" font="font5" id="p1_t59" reading_order_no="56" segment_no="3" tag_type="text">10â€“40% of patients appear to have an inadequate</text>
<text top="110" left="313" width="241" height="9" font="font5" id="p1_t60" reading_order_no="57" segment_no="3" tag_type="text">antiplatelet response to aspirin [28,30]. Such patients<a href="">[28,29]</a>. Depending on the population studied and the</text>
<text top="122" left="313" width="241" height="9" font="font5" id="p1_t61" reading_order_no="58" segment_no="3" tag_type="text">appear to be at increased risk for the development of vas-</text>
<text top="134" left="313" width="241" height="9" font="font5" id="p1_t62" reading_order_no="59" segment_no="3" tag_type="text">cular events. In theory, these aspirin-resistant patients</text>
<text top="145" left="313" width="241" height="9" font="font5" id="p1_t63" reading_order_no="60" segment_no="3" tag_type="text">may derive particular benefit from additional antiplatelet<a href="">28,30].</a> Such patients</text>
<text top="157" left="313" width="54" height="9" font="font5" id="p1_t64" reading_order_no="61" segment_no="3" tag_type="text">therapy [31].</text>
<text top="181" left="313" width="241" height="9" font="font5" id="p1_t65" reading_order_no="62" segment_no="5" tag_type="text">Clopidogrel is a thienopyridine antiplatelet agent that</text>
<text top="192" left="313" width="241" height="9" font="font5" id="p1_t66" reading_order_no="63" segment_no="5" tag_type="text">inhibits ADP-dependent platelet activation and aggrega-</text>
<text top="204" left="313" width="241" height="9" font="font5" id="p1_t67" reading_order_no="64" segment_no="5" tag_type="text">tion [32]. Sevenfold more potent than ticlopidine, clopi-<a href="">y [31].</a></text>
<text top="216" left="313" width="241" height="9" font="font5" id="p1_t68" reading_order_no="65" segment_no="5" tag_type="text">dogrel is free of its adverse side effects such as</text>
<text top="228" left="313" width="241" height="9" font="font5" id="p1_t69" reading_order_no="66" segment_no="5" tag_type="text">neutropenia, diarrhea and rash [33]. Unlike aspirin</text>
<text top="239" left="313" width="241" height="9" font="font5" id="p1_t70" reading_order_no="67" segment_no="5" tag_type="text">[24,34], clopidogrel has been shown to inhibit the process<a href="">tion [32]</a>. Sevenfold more potent than ticlopidine, clopi-</text>
<text top="251" left="313" width="241" height="9" font="font5" id="p1_t71" reading_order_no="68" segment_no="5" tag_type="text">of platelet-mediated intimal proliferation and smooth</text>
<text top="263" left="313" width="241" height="9" font="font5" id="p1_t72" reading_order_no="69" segment_no="5" tag_type="text">muscle hyperplasia in laboratory experiments. In a cell<a href=""> [33</a>]. Unlike aspirin</text>
<text top="275" left="313" width="241" height="9" font="font5" id="p1_t73" reading_order_no="70" segment_no="5" tag_type="text">culture model, clopidogrel significantly inhibited platelet<a href="">[24</a>,<a href="">34], </a>clopidogrel has been shown to inhibit the process</text>
<text top="286" left="313" width="241" height="9" font="font5" id="p1_t74" reading_order_no="71" segment_no="5" tag_type="text">adhesion to immobilized fibrinogen and also inhibited</text>
<text top="298" left="313" width="241" height="9" font="font5" id="p1_t75" reading_order_no="72" segment_no="5" tag_type="text">platelet-dependent mitogenic signaling and DNA synthe-</text>
<text top="310" left="313" width="241" height="9" font="font5" id="p1_t76" reading_order_no="73" segment_no="5" tag_type="text">sis in cultured coronary artery smooth muscle cells [35].</text>
<text top="322" left="313" width="241" height="9" font="font5" id="p1_t77" reading_order_no="74" segment_no="5" tag_type="text">Similarly, in animal thrombosis models, clopidogrel but</text>
<text top="333" left="313" width="241" height="9" font="font5" id="p1_t78" reading_order_no="75" segment_no="5" tag_type="text">not aspirin significantly inhibited platelet-mediated inti-</text>
<text top="345" left="313" width="241" height="9" font="font5" id="p1_t79" reading_order_no="76" segment_no="5" tag_type="text">mal proliferation and smooth muscle hyperplasia<a href="">lls [35</a>].</text>
<text top="357" left="313" width="241" height="9" font="font5" id="p1_t80" reading_order_no="77" segment_no="5" tag_type="text">[33,36]. Furthermore, the combination of clopidogrel</text>
<text top="369" left="313" width="241" height="9" font="font5" id="p1_t81" reading_order_no="78" segment_no="5" tag_type="text">with aspirin led to potent synergistic antithrombotic</text>
<text top="380" left="313" width="241" height="9" font="font5" id="p1_t82" reading_order_no="79" segment_no="5" tag_type="text">effects and a decrease in myointimal proliferation com-</text>
<text top="392" left="313" width="171" height="9" font="font5" id="p1_t83" reading_order_no="80" segment_no="5" tag_type="text">pared to either therapy alone [24,36,37].<a href="">[33</a>,<a href="">36]. Fur</a>thermore, the combination of clopidogrel</text>
<text top="416" left="313" width="241" height="9" font="font5" id="p1_t84" reading_order_no="81" segment_no="7" tag_type="text">Several large clinical trials have demonstrated that clopi-</text>
<text top="427" left="313" width="241" height="9" font="font5" id="p1_t85" reading_order_no="82" segment_no="7" tag_type="text">dogrel reduces ischemic events and mortality in patients</text>
<text top="439" left="313" width="241" height="9" font="font5" id="p1_t86" reading_order_no="83" segment_no="7" tag_type="text">with coronary and vascular disease [38-41]. In the CAPRIE<a href="">e [24,36,37</a>].</text>
<text top="451" left="313" width="241" height="9" font="font5" id="p1_t87" reading_order_no="84" segment_no="7" tag_type="text">(Clopidogrel versus Aspirin in Patients with Ischemic</text>
<text top="463" left="313" width="241" height="9" font="font5" id="p1_t88" reading_order_no="85" segment_no="7" tag_type="text">Events) trial, clopidogrel (75 mg/day) was demonstrated</text>
<text top="474" left="313" width="241" height="9" font="font5" id="p1_t89" reading_order_no="86" segment_no="7" tag_type="text">to be significantly more effective than aspirin (325 mg/<a href="">ase [38-41]. In </a>the CAPRIE</text>
<text top="486" left="313" width="241" height="9" font="font5" id="p1_t90" reading_order_no="87" segment_no="7" tag_type="text">day) in preventing vascular thrombotic events (ischemic</text>
<text top="498" left="313" width="241" height="9" font="font5" id="p1_t91" reading_order_no="88" segment_no="7" tag_type="text">stroke, MI or vascular death) in patients with clinical evi-</text>
<text top="510" left="313" width="241" height="9" font="font5" id="p1_t92" reading_order_no="89" segment_no="7" tag_type="text">dence of atherosclerotic disease (clopidogrel 9.78% vs.</text>
<text top="521" left="313" width="241" height="9" font="font5" id="p1_t93" reading_order_no="90" segment_no="7" tag_type="text">aspirin 10.64%, relative risk reduction [RRR] 8.7%, p =</text>
<text top="533" left="313" width="241" height="9" font="font5" id="p1_t94" reading_order_no="91" segment_no="7" tag_type="text">0.045) [38]. In patients presenting with acute coronary</text>
<text top="545" left="313" width="241" height="9" font="font5" id="p1_t95" reading_order_no="92" segment_no="7" tag_type="text">syndromes, the CURE (Clopidogrel in Unstable angina to</text>
<text top="557" left="313" width="241" height="9" font="font5" id="p1_t96" reading_order_no="93" segment_no="7" tag_type="text">prevent Recurrent ischemic Events) study demonstrated</text>
<text top="568" left="313" width="241" height="9" font="font5" id="p1_t97" reading_order_no="94" segment_no="7" tag_type="text">that the combination of clopidogrel and aspirin was more<a href="">38]. In patient</a>s presenting with acute coronary</text>
<text top="580" left="313" width="241" height="9" font="font5" id="p1_t98" reading_order_no="95" segment_no="7" tag_type="text">effective at reducing the primary outcome (cardiovascular</text>
<text top="592" left="313" width="241" height="9" font="font5" id="p1_t99" reading_order_no="96" segment_no="7" tag_type="text">death, nonfatal MI or stroke) compared to aspirin alone</text>
<text top="604" left="313" width="241" height="9" font="font5" id="p1_t100" reading_order_no="97" segment_no="7" tag_type="text">(clopidogrel and aspirin 9.3% vs. aspirin alone 11.4%,</text>
<text top="615" left="313" width="241" height="9" font="font5" id="p1_t101" reading_order_no="98" segment_no="7" tag_type="text">RRR 20%, p &lt; 0.001) [40]. Subgroup analysis from these</text>
<text top="627" left="313" width="241" height="9" font="font5" id="p1_t102" reading_order_no="99" segment_no="7" tag_type="text">trials suggested that patients that underwent surgical</text>
<text top="639" left="313" width="241" height="9" font="font5" id="p1_t103" reading_order_no="100" segment_no="7" tag_type="text">revascularization also benefited from clopidogrel</text>
<text top="651" left="313" width="241" height="9" font="font5" id="p1_t104" reading_order_no="101" segment_no="7" tag_type="text">[39,42,43]. However, no trial to date has prospectively<a href="">) [40]. Sub</a>group analysis from these</text>
<text top="662" left="313" width="241" height="9" font="font5" id="p1_t105" reading_order_no="102" segment_no="7" tag_type="text">evaluated the combined effects of clopidogrel plus aspirin</text>
<text top="674" left="313" width="185" height="9" font="font5" id="p1_t106" reading_order_no="103" segment_no="7" tag_type="text">on saphenous vein graft disease after CABG.</text>
<text top="698" left="313" width="241" height="9" font="font5" id="p1_t107" reading_order_no="104" segment_no="9" tag_type="text">There currently exists a clinical equipoise regarding the<a href="">[39</a>,<a href="">42,43</a>]. However, no trial to date has prospectively</text>
<text top="709" left="313" width="241" height="9" font="font5" id="p1_t108" reading_order_no="105" segment_no="9" tag_type="text">optimal antiplatelet therapy for patients who have under-</text>
<text top="721" left="313" width="241" height="9" font="font5" id="p1_t109" reading_order_no="106" segment_no="9" tag_type="text">gone coronary artery bypass surgery. While some</text>
</page>
</pdf2xml>
